NanoRepro AG (FRA:NN6)

Market Cap	20.81M
Revenue (ttm)	4.51M
Net Income (ttm)	-2.05M
Shares Out	n/a
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,119
Average Volume	775
Open	1.730
Previous Close	1.735
Day's Range	1.615 - 1.730
52-Week Range	1.170 - 2.100
Beta	n/a
RSI	43.27
Earnings Date	Sep 26, 2025

About NanoRepro AG

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and mi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NN6

Financial Performance

In 2024, NanoRepro AG's revenue was 4.51 million, an increase of 41.68% compared to the previous year's 3.18 million. Losses were -2.05 million, -56.34% less than in 2023.